This was either an off-target effect of pazopanib or imatinib and included five patients with PDGFR (1 GIST), four with FGFR, three with KIT (2 GIST), and two with KDR gene aberrations. The gene discussed is KDR; the disease is gastrointestinal stromal tumor.